Identification and validation of ion channels-related mRNA prognostic signature for glioblastomas

Chao Huang,Xue-Bin Yu,Yong-Zhi Zhou,Wu-Qiao Bao
DOI: https://doi.org/10.1097/md.0000000000040736
IF: 1.6
2024-12-01
Medicine
Abstract:Glioma is the most prevalent primary malignant tumor originating from the central nervous system, and it is characterized by high recurrence and mortality rates. [ 1 , 2 ] The survival probability of patients diagnosed with glioma greatly depends on the glioma grade. [ 3 ] According to the histology characteristics, glioma is usually classified into grade II to IV. [ 1 ] The grade II gliomas were considered as low-grade glioma (LGG), and grade III was an anaplastic glioma, and grade IV glioma was considered as high-grade glioma or glioblastomas (namely GBM). [ 4 , 5 ] The survival time of LGG and anaplastic glioma could be longer than 5 years, but the survival time of GBM is shorter than 1 year. [ 1 ] Previous studies have proved that targeted therapy was useful and promising for tumor treatment, [ 6 , 7 ] but most molecular targeted drugs failed in the treatment of GBM because of their high invasiveness and drug resistance. [ 5 ] Thus, identifying more biomarkers and targeted drugs was meaningful for the GBM treatment.
medicine, general & internal
What problem does this paper attempt to address?